Advanced Gastroesophageal Cancer

Publication Date: January 5, 2023

Key Points

Key Points

  • Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
  • Most gastric and gastrointestinal junction tumors are adenocarcinoma.
  • Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.

Treatment

...reatment

...1. Immunotherapy and Targeted Therapy f...


...t-line Therapy...

...ndation 1.1For HER2-negative patie...

...mendation 1.2For HER2-negative patients with e...

...mmendation 1.3For patients with ESCC an...

Recommendation 1.4For patients with ESC...

...mmendation 1.5For patients with HER2...


...r Third-line Therapy

...n 2.1For patients with advanced gastroesophageal o...

...tion 2.2For HER2-positive patients with gast...